How should metformin be initiated and titrated in an adult with type 2 diabetes and estimated glomerular filtration rate ≥60 mL/min/1.73 m², and what dose adjustments are required for eGFR 45–59, 30–44, or <30 mL/min/1.73 m² and in contraindicated conditions such as heart failure, hepatic disease, pregnancy, or before iodinated contrast?

Metformin Dosing in Type 2 Diabetes

For adults with type 2 diabetes and eGFR ≥60 mL/min/1.73 m², initiate metformin at 500 mg once or twice daily with meals, titrate by 500 mg weekly to a target of 1000 mg twice daily (maximum 2000–2550 mg/day), and monitor eGFR annually. 1, 2

Initial Dosing and Titration (eGFR ≥60 mL/min/1.73 m²)

Starting dose:

• Begin with 500 mg once daily or twice daily with meals to minimize gastrointestinal side effects (nausea, diarrhea, bloating), which are the most common reason for discontinuation 1, 2, 3
• Alternative: 850 mg once daily, though 500 mg is better tolerated 2

Titration schedule:

• Increase by 500 mg increments every 7 days based on glycemic response and tolerability 1, 2
• Target dose: 1000 mg twice daily (2000 mg/day total) 1
• Maximum dose: 2550 mg/day in divided doses, though most patients achieve adequate control at 2000 mg/day 1
• If gastrointestinal symptoms occur during titration, decrease to the previous dose and attempt advancement later 1, 2

Extended-release formulation:

• Start at 500 mg once daily with the evening meal 1
• Titrate by 500 mg every 7 days up to maximum 2000 mg once daily 1
• Provides similar efficacy to immediate-release with improved adherence 1

Monitoring:

• Check eGFR at least annually when ≥60 mL/min/1.73 m² 1, 4
• Reassess A1c 3 months after reaching target metformin dose to determine if additional therapy is needed 1

---

Dose Adjustments for Reduced Renal Function

eGFR 45–59 mL/min/1.73 m² (Mild-Moderate Impairment)

Continue current metformin dose (up to 2000–2550 mg/day) without mandatory reduction in most patients. 1, 4

• Consider dose reduction in elderly patients, those with liver disease, heart failure, or high risk for lactic acidosis 1, 4
• Increase monitoring frequency to every 3–6 months 1, 4
• Population studies show metformin use at this eGFR range is associated with reduced mortality compared to other glucose-lowering agents 4

eGFR 30–44 mL/min/1.73 m² (Moderate-Severe Impairment)

Reduce metformin dose by 50% to a maximum of 1000 mg daily. 1, 4, 2

• Do not initiate metformin in patients not already receiving it 4
• Monitor eGFR every 3–6 months 1, 4
• Carefully reassess benefit-risk balance, especially in frail or highly comorbid patients 4

eGFR <30 mL/min/1.73 m² (Severe Impairment)

Discontinue metformin immediately—this is an absolute contraindication. 1, 4, 5

• Metformin is eliminated unchanged in urine; severe renal impairment causes drug accumulation and substantially increases risk of fatal lactic acidosis 4, 5
• The FDA 2016 label revision established eGFR <30 mL/min/1.73 m² as an absolute contraindication 4, 5

---

Contraindications and Temporary Discontinuation

Absolute Contraindications

Metformin is contraindicated in:

• eGFR <30 mL/min/1.73 m² 4, 5
• Clinical or laboratory evidence of hepatic disease (impaired lactate clearance increases lactic acidosis risk) 5, 6
• Acute or unstable heart failure with hypoperfusion and hypoxemia 5, 6
• History of metformin-associated lactic acidosis 6

Temporary Discontinuation ("Sick-Day Rules")

Hold metformin immediately during:

• Acute illness causing volume depletion (sepsis, severe diarrhea, vomiting, dehydration) 1, 4, 5
• Hospitalization with elevated acute kidney injury risk 1, 4
• Acute decompensated heart failure 4, 5
• Any condition causing hypoxemia or hemodynamic instability 5

Iodinated Contrast Procedures

For patients with eGFR 30–60 mL/min/1.73 m² OR those with liver disease, alcoholism, heart failure, or receiving intra-arterial contrast:

• Stop metformin at the time of contrast administration 4, 5
• Hold for 48 hours after the procedure 4, 5
• Re-measure eGFR at 48 hours; restart only if renal function is stable 4, 5

For patients with eGFR ≥60 mL/min/1.73 m² without additional risk factors:

• May continue through the procedure without interruption 4

---

Special Populations and Monitoring

Pregnancy

Metformin is not FDA-approved for use in pregnancy. While some guidelines support its use in gestational diabetes, this falls outside standard FDA labeling and requires specialist consultation. 5

Elderly Patients (≥65 Years)

• Assess renal function more frequently due to higher likelihood of hepatic, renal, or cardiac impairment 5
• Elderly patients have increased susceptibility to gastrointestinal side effects, dehydration, and reduced appetite 4
• Consider dose reduction even when eGFR is preserved if frail or highly comorbid 4

Vitamin B12 Monitoring

Check vitamin B12 levels in patients on metformin for >4 years, especially those with anemia or peripheral neuropathy. 1, 4, 5

• Approximately 7% develop subnormal B12 levels due to interference with B12-intrinsic factor complex absorption 1, 5
• Deficiency is rapidly reversible with discontinuation or supplementation 5

Concomitant Insulin or Sulfonylureas

• Metformin increases hypoglycemia risk when combined with insulin or insulin secretagogues 5
• Reduce insulin or sulfonylurea dose when adding metformin 5
• Metformin monotherapy does not cause hypoglycemia 3

---

Alternative Therapies When Metformin Is Contraindicated

When metformin must be discontinued (eGFR <30 mL/min/1.73 m²):

First-line alternatives:

• GLP-1 receptor agonists (dulaglutide, liraglutide, semaglutide) with proven cardiovascular benefits 4
• Dulaglutide can be used down to eGFR >15 mL/min/1.73 m² without dose adjustment 4

Second-line alternatives:

• DPP-4 inhibitors with renal dose adjustment 4
  • Sitagliptin: 25 mg daily when eGFR <30 mL/min/1.73 m² 4
  • Linagliptin: no dose adjustment required at any eGFR 4

For patients with cardiovascular disease, heart failure, or CKD:

• Add SGLT2 inhibitor (when eGFR ≥20 mL/min/1.73 m²) for additional cardiovascular and renal protection 1, 4

---

Common Pitfalls and How to Avoid Them

Use eGFR, not serum creatinine alone, to guide dosing decisions. Creatinine-based cutoffs are outdated and may lead to inappropriate discontinuation, especially in elderly or small-statured patients. 4

Do not discontinue metformin prematurely at eGFR 45–59 mL/min/1.73 m². This range is safely above the cessation threshold and associated with mortality benefit. 4

Do not advance doses too quickly if gastrointestinal symptoms occur. Decrease to the previous dose and retry advancement later. 1, 2

Do not fail to implement "sick-day rules." Temporary discontinuation during acute illness prevents drug accumulation and lactic acidosis. 1, 4, 5

Do not initiate metformin in patients with eGFR 30–44 mL/min/1.73 m² who are not already on therapy. 4

Increase monitoring frequency to every 3–6 months once eGFR drops below 60 mL/min/1.73 m². Annual checks are insufficient. 1, 4